(Q46173156)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

title

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

author name string

Aayoung Hong

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Gatien Moriceau

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Lu Sun

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Shirley Lomeli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Robert Damoiseaux

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Sheri L Holmen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Norman E Sharpless

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Willy Hugo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

Roger S Lo

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

publication date

18 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

page(s)

74-93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

describes a project that uses

30 March 2020

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6456057/fullTextXML

inferred from PubMed Central ID database lookup

cites work

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

1 reference

12 December 2020

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

1 reference

12 December 2020

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

12 December 2020

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

1 reference

12 December 2020

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

1 reference

12 December 2020

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

1 reference

12 December 2020

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

1 reference

12 December 2020

Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor

1 reference

12 December 2020

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors

1 reference

12 December 2020

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

12 December 2020

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

1 reference

12 December 2020

GSVA: gene set variation analysis for microarray and RNA-seq data.

1 reference

12 December 2020

TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions

1 reference

12 December 2020

Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression

1 reference

12 December 2020

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma

1 reference

12 December 2020

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

1 reference

12 December 2020

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition

1 reference

12 December 2020

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

1 reference

12 December 2020

Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma

1 reference

12 December 2020

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction

1 reference

12 December 2020

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition

1 reference

12 December 2020

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

1 reference

12 December 2020

BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma.

1 reference

12 December 2020

JASPAR 2016: a major expansion and update of the open-access database of transcription factor binding profiles

1 reference

12 December 2020

Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib.

1 reference

12 December 2020

Regulated necrosis: disease relevance and therapeutic opportunities

1 reference

12 December 2020

Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination.

1 reference

12 December 2020

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.

1 reference

12 December 2020

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

1 reference

12 December 2020

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.

1 reference

12 December 2020

Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.

1 reference

12 December 2020

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

1 reference

12 December 2020

10.1158/2159-8290.CD-17-0682

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28923912%20AND%20SRC:MED&resulttype=core&format=json

30 March 2020

PubMed publication ID

28923912

1 reference